Antonini, Abbruzzese, Barone et Bonuccelli, « COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features », Neuropsychiatric Disease and Treatment, vol. 4, no 1, , p. 1–9 (PMID18728767, PMCID2515921, DOI10.2147/NDT.S2404)
Forsberg, Lehtonen, Heikkinen et Savolainen, « Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat », Journal of Pharmacology and Experimental Therapeutics, vol. 304, no 2, , p. 498–506 (PMID12538800, DOI10.1124/jpet.102.042846)
M. Ellermann, C. Lerner, G. Burgy et A. Ehler, « Catechol-O-methyltransferase in complex with substituted 3′-deoxyribose bisubstrate inhibitors », Acta Crystallographica D, vol. 68, no 3, , p. 253–260 (PMID22349227, DOI10.1107/S0907444912001138)
J. Dingemanse, K. Jorga, G. Zurcher et M. Schmitt, « Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa », British Journal of Clinical Pharmacology, vol. 40, no 3, , p. 253–262 (PMID8527287, PMCID1365105, DOI10.1111/j.1365-2125.1995.tb05781.x)
Jorga, Fotteler, Heizmann et Zürcher, « Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy », European Journal of Clinical Pharmacology, vol. 54, no 5, , p. 443–447 (PMID9754991, DOI10.1007/s002280050490)
Reig, Ventura, Salvadó et Gámez, « SOM0226, a repositioned compound for the treatment of TTR amyloidosis », Orphanet J Rare Dis, vol. 10, no Suppl 1, , P9 (PMCID4642128, DOI10.1186/1750-1172-10-s1-p9)
Truong, « Tolcapone: Review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease », Clinical Interventions in Aging, vol. 4, , p. 109–113 (PMID19503773, PMCID2685232, DOI10.2147/CIA.S3787)
Deleu, Northway et Hanssens, « Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease », Clinical Pharmacokinetics, vol. 41, no 4, , p. 261–309 (PMID11978145, DOI10.2165/00003088-200241040-00003)
K. Jorga, B. Fotteler, P. Heizmann et R. Gasser, « Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase », British Journal of Clinical Pharmacology, vol. 48, no 4, , p. 513–520 (PMID10583021, PMCID2014389, DOI10.1046/j.1365-2125.1999.00036.x)
Forsberg, Huotari, Savolainen et Männistö, « The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration », European Journal of Pharmaceutical Sciences, vol. 24, no 5, , p. 503–511 (PMID15784340, DOI10.1016/j.ejps.2005.01.005)
Novaroli, Bouchard Doulakas, Reist et Rolando, « The Lipophilicity Behavior of Three Catechol-O-methyltransferase (COMT) Inhibitors and Simple Analogues », Helvetica Chimica Acta, vol. 89, no 1, , p. 144–152 (DOI10.1002/hlca.200690007)
Manikumar, Jin et Rehder, « Convenient Synthesis of Tolcapone, a Selective Catechol‐O‐methyltransferase Inhibitor », Synthetic Communications, vol. 38, no 5, , p. 810 (DOI10.1080/00397910701821077)
Antonini, Abbruzzese, Barone et Bonuccelli, « COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features », Neuropsychiatric Disease and Treatment, vol. 4, no 1, , p. 1–9 (PMID18728767, PMCID2515921, DOI10.2147/NDT.S2404)
Forsberg, Lehtonen, Heikkinen et Savolainen, « Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat », Journal of Pharmacology and Experimental Therapeutics, vol. 304, no 2, , p. 498–506 (PMID12538800, DOI10.1124/jpet.102.042846)
M. Ellermann, C. Lerner, G. Burgy et A. Ehler, « Catechol-O-methyltransferase in complex with substituted 3′-deoxyribose bisubstrate inhibitors », Acta Crystallographica D, vol. 68, no 3, , p. 253–260 (PMID22349227, DOI10.1107/S0907444912001138)
J. Dingemanse, K. Jorga, G. Zurcher et M. Schmitt, « Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa », British Journal of Clinical Pharmacology, vol. 40, no 3, , p. 253–262 (PMID8527287, PMCID1365105, DOI10.1111/j.1365-2125.1995.tb05781.x)
Jorga, Fotteler, Heizmann et Zürcher, « Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy », European Journal of Clinical Pharmacology, vol. 54, no 5, , p. 443–447 (PMID9754991, DOI10.1007/s002280050490)
Reig, Ventura, Salvadó et Gámez, « SOM0226, a repositioned compound for the treatment of TTR amyloidosis », Orphanet J Rare Dis, vol. 10, no Suppl 1, , P9 (PMCID4642128, DOI10.1186/1750-1172-10-s1-p9)
Truong, « Tolcapone: Review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease », Clinical Interventions in Aging, vol. 4, , p. 109–113 (PMID19503773, PMCID2685232, DOI10.2147/CIA.S3787)
Deleu, Northway et Hanssens, « Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease », Clinical Pharmacokinetics, vol. 41, no 4, , p. 261–309 (PMID11978145, DOI10.2165/00003088-200241040-00003)
K. Jorga, B. Fotteler, P. Heizmann et R. Gasser, « Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase », British Journal of Clinical Pharmacology, vol. 48, no 4, , p. 513–520 (PMID10583021, PMCID2014389, DOI10.1046/j.1365-2125.1999.00036.x)
Forsberg, Huotari, Savolainen et Männistö, « The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration », European Journal of Pharmaceutical Sciences, vol. 24, no 5, , p. 503–511 (PMID15784340, DOI10.1016/j.ejps.2005.01.005)
scienceblog.com
Press Office, « FDA Talk Paper », New Warnings for Parkinson's Drug, Tasmar, Food and Drug Administration
